Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 12/20 | 0.52 |
| ▸ | RAB9A | P51151 | 11/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.52 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18863906 | 1.00 | PIK3CG (0.67) | PIK3CGNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL18863910 | 0.91 | PIK3CG (0.65) | PIK3CGNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL18877817 | 0.91 | PIK3CG (0.65) | PIK3CGNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL18877818 | 0.91 | PIK3CG (0.65) | PIK3CGNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL18863909 | 0.91 | PIK3CG (0.65) | PIK3CGNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL1179168 | 0.90 | NPC1 (0.57) | PIK3CGNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL18863902 | 0.88 | PIK3CG (0.65) | PIK3CGNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL18877816 | 0.88 | PIK3CG (0.65) | PIK3CGNPC1RAB9APIK3CDPIK3CA | |
| SCHEMBL2994121 | 0.86 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL4566386 | 0.86 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303872-B1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2014-04-16 | — | — | EP | claimed |
| US-8148372-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | claimed |
| EP-2303872-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| US-7888353-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators | ASTRAZENECA AB (SE) | 2011-02-15 | — | — | US | claimed |
| US-20100324044-A1 | METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS | CACCIOLA JOSEPH | 2010-12-23 | — | — | US | claimed |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-12-16 | — | — | US | claimed |
| WO-2009148403-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2017089892-A1 | DEUTERATED ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145002-A1 | DEUTERATED ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145002-A1 | DEUTERATED ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145002-A1 | DEUTERATED ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2017-05-25 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| WO-2009148403-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009148403-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145002-A1 | DEUTERATED ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRM2, GRIN1 | PIK3CG 3457/4885NPC1 2488/4885RAB9A 2850/4885 |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | GRM1, GRM3, GRIN1 | PIK3CG 2627/4885NPC1 2154/4885RAB9A 3344/4885 |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | GRM1, GRM3, GRIN1 | PIK3CG 2539/4885NPC1 2192/4885RAB9A 3167/4885 |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | GRM1, GRM3, GRIN1 | PIK3CG 2627/4885NPC1 2154/4885RAB9A 3344/4885 |
| US-20100324044-A1 | METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS | GRM1, GRM3, GRM2 | PIK3CG 2553/4885NPC1 2263/4885RAB9A 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.